Yong Zeng

Dr. Yong Zeng

Shenzhen Key Laboratory of Reproductive Immunology for Peri-implantation, Shenzhen Zhongshan Institute for Reproduction and Genetics, Shenzhen Zhongshan Urology Hospital, Shenzhen, Guangdong, 518045, PR China.

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
SLSu Liu
Su Liu
YZYong Zeng
Yong Zeng
CHChunyu Huang
Chunyu Huang
YLYuye Li
Yuye Li
YZYong Zeng
Yong Zeng
JKJoanne Kwak-Kim
Joanne Kwak-Kim

1 January 2020 in Fertility and Sterility
Verified
Journal Article
Closed access
YLYuye Li
Yuye Li
SYShuyi Yu
Shuyi Yu
CHChunyu Huang
Chunyu Huang
RLRuochun Lian
Ruochun Lian
CCCong Chen
Cong Chen
YZYong Zeng
Yong Zeng

1 December 2015 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
PLPei-Yan Liang
Pei-Yan Liang
YZYong Zeng
Yong Zeng
CHChun-Yu Huang
Chun-Yu Huang
RLRuo-Chun Lian
Ruo-Chun Lian
XCXian Chen
Xian Chen
YZYong Zeng
Yong Zeng

5 November 2020 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
YLYuye Li
Yuye Li
SXShiru Xu
Shiru Xu
SYShuyi Yu
Shuyi Yu
CHChunyu Huang
Chunyu Huang
SLShenglai Lin
Shenglai Lin
YZYong Zeng
Yong Zeng

21 September 2015 in Nature Immunology
Verified
Journal Article
Closed access
XWXu Dong Wang
Xu Dong Wang
YGYu Gong
Yu Gong
ZCZhi-Long Chen
Zhi-Long Chen
BGBei-Ni Gong
Bei-Ni Gong
JXJi-Ji Xie
Ji-Ji Xie
YLYingqiu Li
Yingqiu Li

25 September 2020 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
SLSu Liu
Su Liu
MMMeilan Mo
Meilan Mo
SXShan Xiao
Shan Xiao
LLLongfei Li
Longfei Li
XHXiuyu Hu
Xiuyu Hu
YZYong Zeng
Yong Zeng
Background: The risk of adverse pregnancy outcomes is increased by having a polycystic ovary syndrome (PCOS) diagnosis. However, the confounders in previous studies preclude firm conclusions, and further studies are warranted. Objectives: To investigate whether PCOS affects pregnancy outcomes and complications in infertile women undergoing their first in vitro fertilization (IVF) treatment, taking into account important confounders. Methods: We performed a retrospective cohort study of 7,678 infertile women, including 666 women with PCOS and 7,012 controls undergoing their first IVF treatment at a private fertility center from January 2010 to December 2017. Our main outcome was the impact of PCOS on adverse pregnancy outcomes (miscarriage, preterm delivery, pregnancy-induced hypertension) and pregnancy outcomes (live birth rate, clinical pregnancy rate, implantation rate). PCOS effects were summarized by adjusted odds ratios (aORs) with 95% confidence intervals (CIs) after controlling for maternal characteristics. Results: After adjusting for differences in maternal age, BMI, infertility duration, total dose of gonadotropin, serum E2 and endometrial thickness on the day of hCG trigger, number of fertilized occytes, number of embryos transferred, embryo type (cleavage-stage embryo or blastocyst) and quality, women with PCOS had an increased risk of developing unfavorable pregnancy complications, including miscarriage (aOR 1.629, 95% CI 1.240–2.141), very preterm delivery (< 32 weeks) (aOR 2.072, 95% CI 1.133–3.791). For pregnancy outcomes, PCOS was associated with higher clinical pregnancy rate (aOR 1.248, 95% CI 1.038–1.501) and implantation rate (aOR 1.238, 95% CI 1.030–1.489) after adjusting for the above-mentioned confounders. Conclusions: Women with PCOS are at increased risk of adverse pregnancy outcomes after adjusting for differences in maternal characteristics. These women may need more frequent medical consultants and management during pregnancy and parturition.